Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Emyria Ltd ( (AU:EMD) ) has issued an update.
Emyria Limited has invited investors to a quarterly webinar on 3 February 2026, where Executive Chairman Greg Hutchinson and COO Mary-Ann Rennie will present the company’s December quarter activities and outline the outlook for the coming quarter. The event underscores Emyria’s ongoing efforts to engage the market on its mental health treatment pipeline, clinical programs and integrated data-driven model, providing shareholders and prospective investors with updated visibility on operational progress and strategic direction in the emerging field of psychedelic-assisted therapies.
The most recent analyst rating on (AU:EMD) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Emyria Ltd stock, see the AU:EMD Stock Forecast page.
More about Emyria Ltd
Emyria Limited is an ASX-listed company that develops and delivers new treatments for mental health and select neurological conditions through an integrated model combining direct clinical services and treatment development. Its operations span Emyria Healthcare, which provides evidence-based care for patients not finding relief from conventional treatments and evaluates emerging therapies such as psychedelic-assisted therapy for PTSD and treatment-resistant depression, and Emyria Data, which gathers robust, ethically sourced real-world data to support its unique therapy and drug development programs focused on psychedelic-assisted therapies and novel drug candidates.
Average Trading Volume: 2,231,737
Technical Sentiment Signal: Buy
Current Market Cap: A$49.2M
Learn more about EMD stock on TipRanks’ Stock Analysis page.